Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Analysts at HC Wainwright boosted their Q3 2027 EPS estimates for shares of Roivant Sciences in a research note issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.44) for the quarter, up from their previous estimate of ($0.47). HC Wainwright has a "Buy" rating and a $48.00 price objective on the stock. The consensus estimate for Roivant Sciences' current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Roivant Sciences' Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($2.09) EPS.
A number of other equities analysts also recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Roivant Sciences in a research note on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Citigroup increased their price target on Roivant Sciences from $46.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, October 28th. UBS Group set a $55.00 price objective on Roivant Sciences in a research report on Wednesday, September 9th. Finally, Sanford C. Bernstein raised Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Roivant Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $46.82.
Read Our Latest Analysis on ROIV
Roivant Sciences Stock Performance
NASDAQ:ROIV opened at $38.96 on Friday. Roivant Sciences has a 52 week low of $19.96 and a 52 week high of $42.50. The firm's fifty day moving average is $37.22 and its 200-day moving average is $32.59. The firm has a market cap of $28.23 billion, a P/E ratio of -61.84 and a beta of 1.23.
Hedge Funds Weigh In On Roivant Sciences
Several institutional investors have recently made changes to their positions in ROIV. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Roivant Sciences in the 2nd quarter valued at $2,166,000. Edgestream Partners L.P. acquired a new position in Roivant Sciences during the third quarter worth $4,626,000. Squarepoint Ops LLC acquired a new position in Roivant Sciences during the second quarter worth $16,830,000. Sumitomo Mitsui DS Asset Management Company Ltd acquired a new position in Roivant Sciences during the third quarter worth $2,257,000. Finally, Arizona State Retirement System raised its holdings in Roivant Sciences by 24.4% during the second quarter. Arizona State Retirement System now owns 128,364 shares of the company's stock worth $4,543,000 after buying an additional 25,199 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Insider Activity at Roivant Sciences
In related news, Director Daniel Gold sold 602,021 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $38.24, for a total transaction of $23,021,283.04. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Melissa B. Epperly sold 17,750 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares in the company, valued at approximately $539,839.40. This represents a 54.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,892,393 shares of company stock worth $110,548,437. Corporate insiders own 8.80% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.